Sugi Predict

Sugi Predict / Targets / LMAN1

LMAN1

Protein ERGIC-53 · P49257 · LMAN1 on Sugi Atlas →

0 patent compounds predicted against LMAN1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to LMAN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 PHASE2RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing PHASE2WITHDRAWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants PHASE1/PHASE2SUSPENDED
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Cardiac Arrhythmias and Sudden Death in Patients Affected With Laminopathies nanUNKNOWN
Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers nanRECRUITING
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans nanUNKNOWN
ASF Alport Patient Registry nanRECRUITING
Genetic Characterization of Parkinson's Disease nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others nanRECRUITING
Biomarkers of Lichen Sclerosus nanUNKNOWN
Genetic Variants in Linear Localized Scleroderma nanCOMPLETED
Molecular and Genetic Studies of Congenital Myopathies nanRECRUITING
Clinical Trial Readiness for the Dystroglycanopathies nanRECRUITING
Imaging Genetics of Laryngeal Dystonia nanRECRUITING
Molecular Analysis of Patients With Neuromuscular Disease nanRECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD) nanCOMPLETED
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism nanCOMPLETED
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy nanRECRUITING
LAMA2-related Muscular Dystrophy Brain Study nanWITHDRAWN
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION
Evaluation of Brain Dysfunction in Patients with Duchene Muscular Dystrophy nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a LMAN1 binder may also engage these)

ProteinNameSimilarity
Q62902 — 1.000 Q62902 →
Q9D0F3 — 0.997 Q9D0F3 →
Q9TU32 — 0.996 Q9TU32 →
Q5RAP2 — 0.968 Q5RAP2 →
Q0V989 — 0.967 Q0V989 →
P49256 — 0.966 P49256 →
Q9DBH5 — 0.966 Q9DBH5 →
Q5NVB3 — 0.965 Q5NVB3 →
Q9WTS6 — 0.965 Q9WTS6 →
O94923 — 0.965 O94923 →
Q9EPS3 — 0.964 Q9EPS3 →
Q5RCF0 — 0.964 Q5RCF0 →
Q6DHL7 — 0.964 Q6DHL7 →
EMC1 ER membrane protein complex subunit 1 0.964 landscape →
Q2NL17 — 0.964 Q2NL17 →
E2RQ08 — 0.963 E2RQ08 →
TNFSF10 Tumor necrosis factor ligand superfamily member 10 0.963 landscape →
Q2HJD1 — 0.963 Q2HJD1 →
Q9Z2G6 — 0.963 Q9Z2G6 →
O70367 — 0.962 O70367 →
F1QR43 — 0.962 F1QR43 →
P59481 — 0.962 P59481 →
Q91YQ5 — 0.962 Q91YQ5 →
P0C204 — 0.962 P0C204 →
Q9CY50 — 0.962 Q9CY50 →
Q4R4T0 — 0.962 Q4R4T0 →
Q8R553 — 0.962 Q8R553 →
Q9D024 — 0.962 Q9D024 →
Q9H0V9 — 0.962 Q9H0V9 →
Q5R7F5 — 0.962 Q5R7F5 →